Introduction
============

Malignant thyroid alterations are characterized by clinical and pathological variations. They are the most frequent malignant alterations of the endocrine system and the number of cases has progressively increased over the last few years ([@b1-ol-06-01-0191]). The annual incidence of thyroid nodules clinically detected in adults is estimated at 0.1%, with a prevalence of 4--7% in investigations using palpation, 30--50% in series that use ultrasound and 50% in autopsies ([@b2-ol-06-01-0191],[@b3-ol-06-01-0191]). Fine-needle aspiration (FNA) represents the main pre-operative tool for diagnosing thyroid nodules, due to its technical simplicity and low cost and a reported sensitivity and specificity of 70--98 and 55--100%, respectively ([@b4-ol-06-01-0191]). However, certain limitations to FNA exist, due to the fact that the material obtained may not be adequate or sufficient, as its volume and quality depend on the technical executor and/or characteristics of the nodule. FNA may also be indeterminate in light of the architectural pattern and the cytological characteristics of the lesion, which may cause misunderstandings, doubts or disagreement, as the diagnosis depends on an interpretation that is frequently based on subtle and subjective criteria ([@b5-ol-06-01-0191]). Indeterminate situations that do not define whether the lesion is malignant represent 10--20% of the cytopathological diagnoses in material obtained from pre-operative FNA of the thyroid. Often, such limitations mean that patients must undergo surgery and all the inherent risks, not as a therapeutic act, but as a diagnostic method. Consequently, the majority of patients undergo surgery and, during the histopathological exam of the excised piece, more than two-thirds of the nodules are classified as benign, indicating that surgery was unnecessary. This creates high hospital costs and causes eventual morbidities associated with radical surgery of the thyroid ([@b6-ol-06-01-0191],[@b7-ol-06-01-0191]). Several studies have reported that tests for the identification of common somatic genetic alterations in thyroid cancer may be useful for diagnostic clarification in samples obtained from indeterminate or suspicious FNA. The RAF protein, via the BRAF isoform, has been one of the most investigated mutations for the diagnosis of nodular thyroid lesions, in isolation or combined with other oncogenes (RAS and RET/PTC) in cytological material, and has presented encouraging results ([@b8-ol-06-01-0191]). The most frequent mutation observed in BRAF involves the translocation of thymine for adenine at position T1799A in exon 15, which causes the substitution of the amino acid valine for glutamic acid at position V600E of the protein. The change in the amino acid activates the protein, as it allows constitutive phosphorylation of the adjacent amino acids, conferring oncogenic capacity ([@b9-ol-06-01-0191],[@b10-ol-06-01-0191]). The objective of the present study was to gather the experiments and results obtained in studies of this oncogene as a way to combine and analyze the contribution of BRAF in pre-operative FNA of the thyroid.

Materials and methods
=====================

A broad review of the literature was conducted using the principles of systematic review. The search strategy included using the electronic bibliographical databases PUBMED, MEDLINE, SCOPUS and LILACS between January 2004 and June 2011. The keywords 'thyroid' and 'fine-needle aspiration' were combined with 'BRAF' and 'molecular marker'. The inclusion criteria were defined as follows: i) The article should have been written in English, French, Italian, Spanish or Portuguese; ii) the main or secondary objective of the study must have been to evaluate the expression of the proto-oncogene BRAF, in isolation or as part of a panel, in material from FNA; iii) the marker should have been submitted for evaluation in samples obtained at the pre-operative phase; and iv) the histopathology of the piece from the surgical resection must have been considered the gold standard of diagnosis. Using these predefined criteria, two of the authors examined the articles that were recovered. The information extracted from the studies included the year of publication, the name of the periodical, the country where the research group was based, the approval register of the experiment conferred by an ethics committee, the distribution of the sample according to gender and age, the number and histological types of the malignant lesions studied in the investigation, the method of analysis of the BRAF gene, the number of cytopathologists involved in the experiment and the identification of other markers when the study involved experiments in panels.

Results
=======

The 37 experiments included in the present study were published in 21 different periodicals and were conducted by research groups in eight countries; there were 12 studies in the United States, 10 in Korea, nine in Italy, two in China, one in Germany, one in Japan, one in France and one in Portugal. All of the studies were written in English, with the exception of one that was published in French. The majority of the studies (72.9%) made reference to the approval of the experiment by an ethics committee or equivalent research body that the institution the group belonged to. No gender differentiation was made with regard to the participants in 51.3% of the studies. The other participants were identified as 1,209 females and 446 males. The age of the participants was not mentioned in 45.9% of the studies. Among the studies that indicated the age, it was possible to observe that the average age was 46.1 years.

In total, the experiments involved 3,029 thyroid malignant lesions, these included 2,732 papillary carcinomas of the thyroid (PTC), 183 follicular variants of papillary carcinoma (FVPTC), 79 follicular carcinomas (FTC), 19 medullary carcinomas (MTC), 11 anaplastic carcinomas (ATC) and five Hürthle cell carcinomas (HCC; [Table I](#t1-ol-06-01-0191){ref-type="table"}). Polymerase chain reaction (PCR) direct sequencing was the predominantly employed method for analyzing the presence of the BRAF gene in the samples. Several studies (67.5%) did not register the number of cytopathologists involved in the process or analysis of the results. In ten studies, the BRAF gene was submitted for analysis in a panel with other markers, particularly the oncogene RET/PTC ([Table II](#t2-ol-06-01-0191){ref-type="table"}). The majority of the studies (75.6%) included samples of indeterminate or suspicious FNA, with 1,366 lesions studied altogether ([Table III](#t3-ol-06-01-0191){ref-type="table"}).

There were no BRAF-positive cases in the FTCs, HCCs or MTCs. Among the 11 ATC cases, three were positive for the BRAF mutation. The number of cases positive for BRAF among the benign lesions was not significant. The average prevalence of BRAF-positive cases of PTC was 58.6%, while in FVPTC, the average prevalence was 29.6%. For lesions with indeterminate or suspicious diagnoses, the average prevalence of BRAF-positive cases of PTC was 48.5%.

Discussion
==========

Thyroid nodules are a common condition, but occasionally represent a challenge in the differentiation of benign and malignant lesions. FNA presents with excellent diagnostic precision in the majority of cases; however, a significant percentage of FNA samples are indeterminate, justifying the efforts of several research groups in identifying molecular markers to improve the diagnostic accuracy of FNA of the thyroid. FNAs that indicate thyroid cancer are rarely false-positive ([@b8-ol-06-01-0191]). In this case, it is possible to conclude that a biomolecular study of the lesion would have little or no importance. However, even such situations justify new approaches, as cytomorphological study of the lesion is not sufficient for the risk stratification and/or proper establishment of medical management measures of the lesion. In this regard, the BRAF mutation has received special attention in the last few years.

Among the four types of thyroid carcinoma, PTC is the most prevalent, responsible for 80--90% of all malignant neoplasms of the thyroid ([@b10-ol-06-01-0191],[@b11-ol-06-01-0191]) and its incidence has been growing rapidly in several areas of the world ([@b12-ol-06-01-0191]). The samples of the experiments included in the present study revealed an average prevalence of PTC in the order of 96% \[(2,732 + 183) / 3,029 × 100\]. It is in this type of lesion that there is a more frequent occurrence of the BRAF mutation. It has been reported that the mutation is present in between 28.8 and 69% of PTCs ([@b13-ol-06-01-0191]). In the present series, an average prevalence of 58.6±20.8% (range, 15--91%) was obtained. PTC is frequently associated with an excellent prognosis and low mortality, but not all patients share such a result ([@b14-ol-06-01-0191]). This is mainly due to inaccurate information concerning the aggressiveness and level of the tumor in the pre-operative phase ([@b11-ol-06-01-0191]).

Several studies ([@b11-ol-06-01-0191],[@b15-ol-06-01-0191]--[@b17-ol-06-01-0191]) have identified the existence of controversy with regard to surgical planning for patients whose cytological aspirations were malignant or indeterminate, and with regard to whether they should undergo partial or total thyroidectomy. In certain cases of lobectomy, the excised nodule is malignant in the histopathological exam, which inevitably requires a second surgery to complete the thyroidectomy, generating additional costs and increasing the possibility of complications and morbidity.

The analysis of the presence of the BRAF mutation in the material obtained from pre-operative FNA is a useful strategy for the reduction of such imprecision and controversies. The specificity with this analysis has been reported at 100% ([@b18-ol-06-01-0191]), i.e. BRAF mutations are not identified in benign lesions, instead being present only in malignant lesions, particularly PTCs. The presence of the BRAF mutation does not identify malignant lesions totally (low sensibility), although its presence does offer the certainty of the result being a true positive. Moreover, it has been suggested that individuals whose nodules exhibit the BRAF mutation are patients who are more likely to be submitted for total thyroidectomy surgery, independently from the cytological results ([@b4-ol-06-01-0191]). In addition, in PTC, the BRAF mutation is intimately associated with extra-thyroidean extension, lymph node metastasis and advanced tumor stages ([@b19-ol-06-01-0191],[@b20-ol-06-01-0191]), which are the main clinicopathological risk factors conventionally associated with the increase of recurrence and mortality rates for thyroid cancer ([@b21-ol-06-01-0191]). Although there are controversies ([@b13-ol-06-01-0191],[@b46-ol-06-01-0191],[@b47-ol-06-01-0191]), the conclusions of a meta-analytical study by Lee *et al* ([@b20-ol-06-01-0191]) revealed the absence of any correlation between the marker and the patients' ethnicity, age, gender or tumor size. With such qualifications, the detection of the BRAF mutation in pre-operative FNA makes it possible to speed up patient management, while avoiding other less specific diagnostic tests, such as FNA repetition, scintigraphy or freezing intraoperative assessment ([@b22-ol-06-01-0191]), as well as the decision concerning the extension of surgical resection to prevent the performance of a second surgery ([@b18-ol-06-01-0191]).

However, it is clear that the frequency of the BRAF mutation does not occur in a uniform manner among the PTC variants. BRAF mutations are more frequent in the high cell variant, followed by the conventional type and then the follicular variant ([@b20-ol-06-01-0191]). In the specific case of FVPTC in the present study, the average prevalence of the BRAF mutation was 29.6%. This PTC variant deserves special attention as the cytological diagnosis may be difficult due to the super-imposition of morphological characteristics with benign or non-neoplastic lesions ([@b17-ol-06-01-0191]). The presence of positivity for the BRAF mutation is not a predictive factor of a worst prognosis in FVPTC as it is largely considered in the other PTC variants ([@b22-ol-06-01-0191]).

A number of the experiments on the BRAF mutation included in the present study were performed in panel form, mainly with other oncogenes (RAS and RET/PTC). The objective of these experiements was to increase the pre-operative FNA diagnostic sensibility, as the BRAF mutation does not occur together with the RAS mutation or the RET-PTC rearrangement, indicating different genetic alterations in the pathogenesis of the papillary carcinoma ([@b9-ol-06-01-0191]).

In conclusion, considering the association between the BRAF mutation and tumor extension and aggressiveness, we recommend that the establishment of a BRAF mutation detection routine should be analyzed in order to apply this approach in morphologically suspicious or indeterminate FNA, and for pre-operative planning for thyroid cancer.

###### 

Studies, analysis method, number of malignant lesions and results of BRAF detection in FNA pre-operative.

  First author (ref.)                         Year   Analysis method                                                                                 Number of malignant lesions / BRAF+                             
  ------------------------------------------- ------ ----------------------------------------------------------------------------------------------- ------------------------------------- ------ ------ ----- ----- -----
  Salvatore *et al* ([@b17-ol-06-01-0191])    2004   PCR - direct sequencing/SSCP                                                                    47/23                                 22/3                      
  Cohen *et al* ([@b22-ol-06-01-0191])        2004   PCR direct sequencing and Mutector assay                                                        27/18                                 27/4   2/0    1/0   1/1   1/0
  Hayashida *et al* ([@b13-ol-06-01-0191])    2004   PCR - RFLP                                                                                      21/5                                                            
  Xing *et al* ([@b23-ol-06-01-0191])         2004   PCR - colorimetric mutation detection method                                                    16/7                                         5/0    1/0         
  Domingues *et al* ([@b24-ol-06-01-0191])    2005   PCR - Direct sequencing                                                                         11/3                                         1/0                1/0
  Chung *et al* ([@b25-ol-06-01-0191])        2006   PCR - Direct sequencing                                                                         107/92                                       3/0          2/1   
  Jin *et al* ([@b26-ol-06-01-0191])          2006   PCR - Direct sequencing, colorimetric Mutector assay, LightCycler PCR and allele-specific PCR   45/29                                 13/2                      
  Rowe *et al* ([@b16-ol-06-01-0191])         2006   LightCycler PCR                                                                                 19/3                                                            
  Pizzolanti *et al* ([@b27-ol-06-01-0191])   2007   Real-time allele-specific-PCR                                                                   14/10                                 2/1    1/0                
  Sapio *et al* ([@b28-ol-06-01-0191])        2007   PCR-MASA                                                                                        6/4                                          1/0                1/0
  Sapio *et al* ([@b18-ol-06-01-0191])        2007   PCR-MASA                                                                                        21/10                                        5/0                
  Kim *et al* ([@b29-ol-06-01-0191])          2008   PCR-Pyrosequencing                                                                              73/63                                 2/0    3/0          1/0   1/0
  Zatelli *et al* ([@b4-ol-06-01-0191])       2009   PCR-Direct sequencing/RFLP                                                                      58/41                                 16/6   7/0          1/1   6/0
  Nikiforov *et al* ([@b15-ol-06-01-0191])    2009   LightCycler PCR/FMCA                                                                            38/18                                        6/0          2/0   2/0
  Moon *et al* ([@b30-ol-06-01-0191])         2009   PCR - Direct sequencing                                                                         84/42                                                           
  Marchetti *et al* ([@b31-ol-06-01-0191])    2009   PCR - Direct sequencing                                                                         89/59                                                     2/0   
  Bentz *et al* ([@b32-ol-06-01-0191])        2009   LightCycler PCR/FMCA                                                                            24/18                                 16/6                      
  Kwak *et al* ([@b21-ol-06-01-0191])         2009   PCR - Direct sequencing                                                                         339/213                                                         
  Xing *et al* ([@b11-ol-06-01-0191])         2009   PCR - Colorimetric mutation detection method                                                    149/68                                41/5                      
  Yip *et al* ([@b14-ol-06-01-0191])          2009   PCR-FMCA                                                                                        44/31                                                           
  Kim *et al* ([@b33-ol-06-01-0191])          2009   PCR - Pyrosequencing                                                                            101/88                                                          
  Jo *et al* ([@b34-ol-06-01-0191])           2009   PCR - Pyrosequencing                                                                            40/30                                                           
  Hwang *et al* ([@b12-ol-06-01-0191])        2010   PCR - Direct sequencing and allele-specific PCR                                                 135/106                                                         
  Lin *et al* ([@b35-ol-06-01-0191])          2010   PCR - Direct sequencing                                                                         61/21                                                           
  Dujardin *et al* ([@b36-ol-06-01-0191])     2010   PCR - Direct sequencing                                                                         10/7                                                            
  Girlando *et al* ([@b37-ol-06-01-0191])     2010   PCR - Direct sequencing                                                                         44/34                                 16/9                      
  Musholt *et al* ([@b38-ol-06-01-0191])      2010   PCR - MASA                                                                                      22/9                                         4/0          1/0   1/0
  Kim *et al* ([@b39-ol-06-01-0191])          2010   DPO-based multiplex PCR                                                                         263/221                                      4/0                1/0
  Guo *et al* ([@b40-ol-06-01-0191])          2010   PCR - Direct sequencing                                                                         8/4                                                             
  Kwak *et al* ([@b41-ol-06-01-0191])         2010   DPO-Based Multiplex PCR                                                                         107/86                                2/1                       
  Ohori *et al* ([@b42-ol-06-01-0191])        2010   LightCycler PCR                                                                                 20/3                                                            
  Moses *et al* ([@b43-ol-06-01-0191])        2010   PCR - Direct sequencing                                                                         70/20                                 19/3   8/0    2/0   1/0   1/0
  Cantara *et al* ([@b8-ol-06-01-0191])       2010   PCR - Direct sequencing                                                                         74/33                                        3/0    1/0         
  Kim *et al* ([@b44-ol-06-01-0191])          2011   PCR- Pyrosequencing                                                                             169/154                                      4/0                
  Yeo *et al* ([@b45-ol-06-01-0191])          2011   PCR- Pyrosequencing                                                                             175/95                                7/4    6/0                4/0
  Adeniran *et al* ([@b46-ol-06-01-0191])     2011   PCR - Direct sequencing/SSCP                                                                    60/40                                                           
  Pelizzo *et al* ([@b47-ol-06-01-0191])      2011   PCR - Direct sequencing/MASA                                                                    141/98                                       16/0               

FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; HCC, Hürthle cell carcinoma; ATC, anaplastic thyroid carcinoma; MTC, medullary thyroid carcinoma; PCR, polymerase chain reaction; MASA, mutant allele-specific amplification; DPO, dual-priming oligonucleotide; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformational polymorphism; FMCA, fluorescence melting curve analysis.

###### 

Distribution of studies according to the types and quantity of markers used in panel with the BRAF gene.

  First author (ref.)                         Year   Markers used
  ------------------------------------------- ------ -------------------------------------------------------------------------------------------------------------------------
  Cantara *et al* ([@b8-ol-06-01-0191])       2010   BRAF, RET, RAS, TRK[^a^](#tfn2-ol-06-01-0191){ref-type="table-fn"}, PAX8[^a^](#tfn2-ol-06-01-0191){ref-type="table-fn"}
  Salvatore *et al* ([@b17-ol-06-01-0191])    2004   BRAF, RET
  Moses *et al* ([@b43-ol-06-01-0191])        2010   BRAF, RET, RAS
  Nikiforov *et al* ([@b15-ol-06-01-0191])    2009   BRAF, RET, RAS, PAX8[^b^](#tfn3-ol-06-01-0191){ref-type="table-fn"}
  Musholt *et al* ([@b38-ol-06-01-0191])      2010   BRAF, RET
  Sapio *et al* ([@b18-ol-06-01-0191])        2007   GAL-3, BRAF
  Sapio *et al* ([@b28-ol-06-01-0191])        2007   BRAF, RET, TRK[^a^](#tfn2-ol-06-01-0191){ref-type="table-fn"}
  Pizzolanti *et al* ([@b27-ol-06-01-0191])   2007   BRAF, RET
  Domingues *et al* ([@b24-ol-06-01-0191])    2004   BRAF, RET
  Ohori *et al* ([@b42-ol-06-01-0191])        2010   BRAF, RET, RAS, PAX8[^b^](#tfn3-ol-06-01-0191){ref-type="table-fn"}

No mutation in the samples selected.

Only one mutation present in the sample.

###### 

Distribution of studies according to number of thyroid papillary carcinomas in the indeterminate or suspicious cytological samples and the number positive for BRAF mutation.

  First author (ref.)                         Total of FNAs   Indeterminate or suspicious lesions / PTC number       Indeterminate or suspicious lesions / BRAF^+^
  ------------------------------------------- --------------- ------------------------------------------------------ -----------------------------------------------
  Moses *et al* ([@b43-ol-06-01-0191])        196             137/33 (19 FVPTC)                                      137/13 (3FVPTC)
  Cantara *et al* ([@b8-ol-06-01-0191])       235             95/53                                                  95/23
  Nikiforov *et al* ([@b15-ol-06-01-0191])    86              52/17                                                  52/7
  Sapio *et al* ([@b18-ol-06-01-0191])        144             94/2                                                   94/10
  Rowe *et al* ([@b16-ol-06-01-0191])         24              19/19                                                  19/3
  Salvatore *et al* ([@b17-ol-06-01-0191])    96              34/15 (6 FVPTC)                                        34/4 (1 FVPTC)
  Xing *et al* ([@b11-ol-06-01-0191])         45              25/7                                                   25/2
  Cohen *et al* ([@b22-ol-06-01-0191])        91              55/29 (21 FVPTC)                                       55/5 (2 FVPTC)
  Musholt *et al* ([@b38-ol-06-01-0191])      93              19/4                                                   19/1
  Dujardin *et al* ([@b36-ol-06-01-0191])     25              13/7                                                   13/4
  Kim *et al* ([@b39-ol-06-01-0191])          279             80/70                                                  80/50
  Kwak *et al* ([@b41-ol-06-01-0191])         130             30/20                                                  30/16
  Ohori *et al* ([@b42-ol-06-01-0191])        117             117/20                                                 117/3
  Moon *et al* ([@b30-ol-06-01-0191])         91              91/84                                                  91/42
  Marchetti *et al* ([@b31-ol-06-01-0191])    111             52/33                                                  33/18
  Bentz *et al* ([@b33-ol-06-01-0191])        45              17/17                                                  17/3
  Jo *et al* ([@b34-ol-06-01-0191])           101             24/9                                                   24/7
  Pizzolanti *et al* ([@b27-ol-06-01-0191])   156             19/3 (1 FVPTC)                                         19/2 (1FVPTC)
  Sapio *et al* ([@b28-ol-06-01-0191])        132             37/6                                                   37/4
  Chung *et al* ([@b25-ol-06-01-0191])        137             25/5                                                   25/3
  Domingues *et al* ([@b24-ol-06-01-0191])    24              10/1                                                   10/0
  Hayashida *et al* ([@b13-ol-06-01-0191])    21              1/1                                                    1/1
  Yeo *et al* ([@b45-ol-06-01-0191])          209             63/49 (5 FVPTC)                                        63/14 (3 FVPTC)
  Adeniran *et al* ([@b46-ol-06-01-0191])     72              34/22                                                  34/10
  Pelizzo *et al* ([@b47-ol-06-01-0191])      270             164/45                                                 164/30
  Jin *et al* ([@b26-ol-06-01-0191])          71              12/([^a^](#tfn4-ol-06-01-0191){ref-type="table-fn"})   12/1
  Girlando *et al* ([@b37-ol-06-01-0191])     91              20/14                                                  20/10
  Kim *et al* ([@b29-ol-06-01-0191])          103             27/18 (2 FVPTC)                                        27/13

Not determined. FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma.
